Gilead Sciences (GILD) : Brave Asset Management Inc scooped up 2,562 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 28,747 shares of Gilead Sciences which is valued at $2,287,399.Gilead Sciences makes up approximately 1.49% of Brave Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Mckinley Carter Wealth Services boosted its stake in GILD in the latest quarter, The investment management firm added 7 additional shares and now holds a total of 8,166 shares of Gilead Sciences which is valued at $654,015. Gilead Sciences makes up approx 0.33% of Mckinley Carter Wealth Services’s portfolio.Blue Fin Capital boosted its stake in GILD in the latest quarter, The investment management firm added 85 additional shares and now holds a total of 7,458 shares of Gilead Sciences which is valued at $592,687. Gilead Sciences makes up approx 0.48% of Blue Fin Capital’s portfolio.Dorchester Wealth Management Co boosted its stake in GILD in the latest quarter, The investment management firm added 24,280 additional shares and now holds a total of 58,815 shares of Gilead Sciences which is valued at $5,090,438. Gilead Sciences makes up approx 1.84% of Dorchester Wealth Management Co’s portfolio.Oakbrook Investments boosted its stake in GILD in the latest quarter, The investment management firm added 53,370 additional shares and now holds a total of 390,440 shares of Gilead Sciences which is valued at $33,792,582. Gilead Sciences makes up approx 1.81% of Oakbrook Investments’s portfolio.
Gilead Sciences opened for trading at $79.46 and hit $80.87 on the upside on Wednesday, eventually ending the session at $80.7, with a gain of 1.83% or 1.45 points. The heightened volatility saw the trading volume jump to 1,05,83,799 shares. Company has a market cap of $106,496 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.